SCHEMBL6489237

SCHEMBL6489237

Cc1ccc(-c2ccc(Cl)cc2)c(C(=O)Nc2ccc(OCCc3csc(C)n3)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.46
F10 P00742 5/20 0.44
LMNA P02545 2/20 0.43
TP53 P04637 1/20 0.43
NPC1 O15118 5/20 0.42
RAB9A P51151 5/20 0.42
KDM4E B2RXH2 2/20 0.42
TAS1R3 Q7RTX0 1/20 0.42
TAS1R1 Q7RTX1 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ANO1 Q5XXA6 1/20 0.42
GCGR P47871 1/20 0.42
STAT1 P42224 2/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
RXFP1 Q9HBX9 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6499318 0.95 MAPT (0.49) MAPTTP53NPC1RAB9AKDM4E
SCHEMBL6497776 0.93 GCGR (0.49) MAPTF10LMNATP53NPC1
SCHEMBL6501928 0.91 SMN1; SMN2 (0.53) MAPTF10LMNATP53NPC1
SCHEMBL6502718 0.91 MAPT (0.44) MAPTF10LMNATP53KDM4E
SCHEMBL6489479 0.89 TP53 (0.47) MAPTLMNATP53NPC1RAB9A
SCHEMBL6499843 0.86 SMN1; SMN2 (0.47) MAPTF10LMNATP53NPC1
SCHEMBL6502572 0.86 SMN1; SMN2 (0.60) MAPTTP53NPC1RAB9AKDM4E
SCHEMBL6489534 0.85 SMN1; SMN2 (0.43) MAPTLMNATP53NPC1RAB9A
SCHEMBL6488351 0.84 SMN1; SMN2 (0.53) MAPTF10LMNATP53NPC1
SCHEMBL6499999 0.84 PPARG (0.49) F10TP53NPC1RAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 MAPT 4202/4885F10 712/4885LMNA 629/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.